Lv4
430 积分 2022-12-15 加入
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
8小时前
已完结
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
8小时前
已完结
Evolution of TROP2: Biological insights and clinical applications
8天前
已关闭
Multiple myeloma
1个月前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
1个月前
已完结
Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation
2年前
已完结
Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors
2年前
已完结
PARPi用于初治卵巢上皮性癌患者一线维持治疗的真实世界临床数据分析
2年前
已完结
Combining PARP Inhibitor With Immunotherapy—Does the Promise of Preclinical Data Translate to Clinic?
2年前
已完结
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
2年前
已完结
皖公网安备34019202002308
